O
steomyelitis is defined as any inflammatory process in bone, the most common cause of which is infection. Although many bacterial pathogens have been associated with osteomyelitis, Staphylococcus aureus is the predominant cause and the pathogen responsible for the most serious forms of bone infection (1) . Given the increasing prevalence of S. aureus strains resistant to methicillin (2) , vancomycin remains the most commonly used antibiotic for the treatment of these infections (3) . While true vancomycin resistance is rare, S. aureus strains with reduced susceptibility are common and often arise as a consequence of the prolonged periods of vancomycin therapy required to treat bone infections (1, 4) . Vancomycin acts by inhibiting bacterial cell wall biosynthesis (5, 6) and is a large hydrophilic molecule that has limited penetration into bone and therefore low bone bioavailability when administered systemically (7) . These factors emphasize the need to develop methods to enhance delivery of vancomycin to bone in the treatment of osteomyelitis. One way to accomplish this is to employ local antibiotic delivery, which while useful suffers from inherent limitations, not the least being the ability to gain direct access to the infection site (8) (9) (10) (11) (12) (13) (14) (15) (16) . Thus, one of the major challenges to improve therapeutic outcomes for osteomyelitis patients is to develop methods for the systemic deliv-ery of vancomycin, and potentially other antibiotics, in sufficient concentrations to achieve the desired therapeutic effect.
Previous studies in our laboratories have led to the development of bone-targeting agents (BT) based on their high affinity for hydroxyapatite and an enhanced tendency to accumulate in bone (17) . We demonstrated that these compounds can be conjugated to vancomycin via a modified polyethylene glycol (PEG) linker ( Fig. 1) to form BT-2-minipeg-2-vancomycin (BT-vancomycin) (18) (19) (20) . Previous in vitro studies confirmed that the MICs of BT-vancomycin against methicillin-resistant and methicillin-susceptible S. aureus are comparable to those of vancomycin alone and that BT-vancomycin binds to hydroxyapatite to a greater extent than vancomycin (21) . The objective of the present study was to define the pharmacokinetic (PK) profiles of vancomycin and BT-vancomycin after systemic administration via intravenous (i.v.) or intraperitoneal (i.p.) routes and to determine the plasma and bone content of vancomycin versus BT-vancomycin.
All experimental animal protocols were in strict accordance with the NIH "Guide for the Care and Use of Laboratory Animals" (24) and were approved by the Institutional Animal Care and Use Committees at the University of Kentucky, Lexington, KY, and Mayo Clinic, Rochester, MN. Thirty-five rats received a single i.v. injection via the tail vein of either vancomycin HCl (50 mg/kg of body weight) or BT-vancomycin (63.85 mg/kg; molar equivalent of 50 mg/kg of vancomycin HCl). Twenty rats were given an i.p. injection of either vancomycin HCl (50 mg/kg) or BT-vancomycin (63.85 mg/kg) twice daily for a total of seven doses. BT-vancomycin and vancomycin levels in plasma and bone were determined by liquid chromatography-tandem mass spectrometry (LC/MS-MS).
Bone samples (frozen tibiae) were pulverized, and the crushed bones were weighed, placed into 2-ml tubes, and stored at Ϫ80°C for further analysis. Analysis of vancomycin and BT-vancomycin was carried out using a Shimadzu LC unit coupled to an ABI 4000-Qtrap hybrid linear ion trap triple-quadrupole mass spectrometer in the multiple reaction monitoring (MRM) mode. Teicoplanin was used as an internal standard.
PK analysis was performed using data from individual rats, for which the mean and standard error of the mean (SEM) were calculated for each group. PK parameters were estimated using a noncompartmental model (Phoenix WinNonlin, Professional, version 6.2; Pharsight, Mountain View, CA). The levels of vancomycin and BT-vancomycin in plasma peaked at 13.00 Ϯ 1.96 and 41.22 Ϯ 8.71 M, respectively, 1 h after administration (Fig. 2) . The concentration of BT-vancomycin in plasma declined to its lowest levels (0.07 Ϯ 0.02 M) at 168 h, while vancomycin reached its lowest level 12 h after i.v. administration (Fig. 2) . Compared to the peak concentrations in plasma, peak concentrations in bone were delayed, with peak concentrations occurring 6 h after i.v. administration (Fig. 3) . The amount of BT-vancomycin in bone was approximately 5-fold higher than that of vancomycin during the initial 12-h period but increased progressively to approximately 47-fold at 168 h (Table 1) .
Increased accumulation of BT-vancomycin was also confirmed after i.p. administration of seven doses of 50 mg/kg of vancomycin or the molar equivalent of BT-vancomycin at 12-h intervals. The ratios of BT-vancomycin to vancomycin were 7.8, 7.4, and 47.7 at 1, 6, and 12 h after the last i.p. administration Results are the mean Ϯ SEM (n ϭ 5 rats). *, significantly higher than results for vancomycin, P Ͻ 0.05; **, significantly higher than results for vancomycin, P Ͻ 0.01; ***, significantly higher than results for vancomycin, P Ͻ 0.0001. Results are the mean Ϯ SEM (n ϭ 5 rats per group). *, significantly higher than results for vancomycin, P Ͻ 0.05; **, significantly higher than results for vancomycin, P Ͻ 0.01; ***, significantly higher than results for vancomycin, P Ͻ 0.001. ( Table 2 ). PK parameters obtained after i.v. administration are detailed in Table 3 . These data demonstrate that vancomycin and BT-vancomycin exhibit significant differences in their PK profiles. A decrease in total clearance (CL tot ) of 13.5-fold was observed for BT-vancomycin compared to vancomycin, with a 14.7-fold increase in half-life (t 1/2 ) allowing for a 10.8-fold enhancement in the area under the concentration-time curve (AUC). The significant changes in the AUC indicate a higher degree of in vivo exposure to BT-vancomycin, facilitating the accumulation of drug in bone due to an enhanced permeation and retention effect. Consequently, BT-vancomycin shows a longer systemic mean residence time (MRT) than vancomycin (P Ͻ 0.001). The higher MRT value of BT-vancomycin could be due in part to a more protracted steady state in vivo, resulting in improved delivery, dramatically increased access into bones, and prolonged exposure in bone tissue (Table 3) .
The estimates of the maximum concentration of drug in serum (C max ) of vancomycin and BT-vancomycin determined in the present study were in agreement with previously published data, which include therapeutic peak and trough serum concentrations of 20.7 to 27.6 M and 3.5 to 6.9 M, respectively (22) .
In our experiments, levels of BT-vancomycin in bone were above the MIC of vancomycin for up to 168 h after administration. These findings predict good antimicrobial outcomes, since the antimicrobial activity of vancomycin is time dependent and not concentration dependent (23) .
In conclusion, our previously published work with BT-vancomycin showed that this novel molecule had in vitro activity similar to that of vancomycin against both methicillin-resistant and methicillin-susceptible S. aureus strains isolated from bone infections (21) . Additionally, BT-vancomycin was shown to be more efficacious than an equimolar dose of vancomycin in a rat osteomyelitis model. However, the most efficacious dosing regimen used in these studies (i.p. injection every 12 h for 21 days) not only was associated with high BT-vancomycin levels in plasma but also caused a decrease in body weight, an elevation in white blood cell count, renal dysfunction, and evidence of tubulointerstitial nephritis. Although we did not examine toxicity in the current studies, we have demonstrated enhanced accumulation in bone, even after a single i.v. dose of an amount of BT-vancomycin equivalent to that used in the previous study (21) . Thus, with further dose optimization, this toxicity can likely be minimized, making BTvancomycin a useful BT therapy for the treatment of methicillinresistant S. aureus (MRSA) osteomyelitis. More importantly, the results justify future studies to assess the utility of our promising BT agent in the context of other, less toxic antibiotics that have activity against MRSA.
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